Michael Myers - 01 Jan 2023 Form 3 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Role: Chief Executive Officer, Director
Signature: /s/ Michael Myers
Issuer symbol: QNRX
Transactions as of: 01 Jan 2023
Net transactions value: $0
Form type: 3
Filing time: 03 Jan 2023, 08:47:21 UTC
Next filing: 30 Oct 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	QNRX	Ordinary Shares						561,480,000	01 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	QNRX	Share Option (right to buy)							01 Jan 2023	Ordinary Shares	428,571,600	$0.003500	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents five thousand (5,000) ordinary shares of the Issuer.
F2	The option vests in four equal annual installments beginning on April 12, 2023.
F3	The number of securities underlying the option and the exercise price are listed in terms of ordinary shares, with five thousand (5,000) ordinary shares of the Issuer represented by one (1) ADS, which evidences the grant of an option to buy 85,714.32 ADSs at the exercise price of $17.50 per ADS.